NICO Launches Investigator Initiated Study Program to Increase Scientific Data Supporting Minimally Invasive Neurosurgery

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

NICO Corporation, a neurosurgical medical device maker, has launched an Investigator Initiated Study (IIS) Program offering financial support for prospective studies or the evaluation of retrospective data related to improved patient and economic outcomes using minimally invasive neurosurgery approaches.

NICO has invested more than $8 million in clinical research supporting true minimally invasive neurosurgery approaches using automated technologies for subcortical and skull base procedures.

“NICO has been a leader in accumulating meaningful scientific data and bringing that to the market in ways that significantly benefit patients and healthcare institutions,” said Mark Rosenblum, MD, member of the NICO Board of Directors and Chairman Emeritus of the Department of Neurosurgery in the Henry Ford Health System. “Their focus of obtaining scientific evidence and promoting safe approaches to brain disorders is unique and I believe will have a lasting impact on the field of neurosurgery.”

The IIS Program supports physicians, residents or fellows in neurosurgery who are committed to building clinical and scientific data to validate minimally invasive brain surgery in achieving better outcomes for patients and healthcare providers, as well as expanding the body of evidence. Studies are encouraged that evaluate:

  • Scientific justification of “why access matters” through studying the impact on brain structure, function and eloquent tissues when fascicular anatomy, vascular integrity and critical white matter tracts are preserved.
  • Disease state applications and understanding of pathophysiology, metastatic spread and recurrence of primary and secondary brain tumors.
  • Validation of an optimized and standardized tissue procurement and preservation system for future genomic-, proteomic- and immunologically-directed precision medicine clinical trials.
  • Enhanced Recovery After Neurological Surgery (ERANS) protocols and other economic benefits to minimally invasive neurosurgery.

“NICO is working to increase its scientific footprint by using content published through the program to identify scientific signals for efficacy, proof of concept applications, or guide specific areas of study that may improve clinical outcomes for patients with abnormalities in the brain,” said Penny Sekerak, Vice President of Professional Education and Clinical Affairs for NICO. “This will be a highly competitive process with numerous studies approved. Our ultimate goal is to advocate the advancement of scientific support for minimally disruptive neurosurgery that achieves improved patient and economic outcomes.”

Requests for support are being accepted now and will be reviewed for scientific merit, feasibility, possible contribution to the respective body of clinical knowledge, and compatibility with NICO’s long-term clinical and scientific focus. Only U.S. sites or its territories are eligible. Learn more about the NICO IIS Program here.  or submit questions here.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.